Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TPBG (5T4) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TPBG ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View TPBG Products |
| Gene Delivery | TPBG Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View TPBG Products |
| Benchmark Ab | Anti-TPBG (Sequence of MEDI0641) Recombinant positive control. Sequence Verified. |
View TPBG Products |
| Validator | TPBG siRNA Set For knockdown verification. |
View TPBG Products |
| Related Target A | ERBB2 Synergistic pathway / Combination therapy in breast and gastric cancers. |
View ERBB2 Products |
| Related Target B | TACSTD2 TROP2 - Parallel biomarker for broad solid tumor targeting. |
View TACSTD2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity and strictly verified by mass spec. |
| ADC Internalization Assays | HEK293 expressed ECD-Fc preserving native glycosylation for accurate receptor binding and internalization kinetics. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included with precise Theoretical MW and sequence verification. |
| False Positives in Screening | Validated siRNA included for rigorous specificity and knockdown checks. |
Live TPBG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TPBG (5T4) therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and T-cell engagers. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly specific, low-toxicity combinations designed to tackle refractory solid tumors, leveraging TPBG's highly restricted expression pattern in normal tissues vs. broad expression in carcinomas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | AstraZeneca, Byondis | Solid Tumors (Breast, Ovarian) | Internalization Assay (Need high-purity HEK293 ECD-Fc) |
| Bispecific / TCE | Harpoon Therapeutics (HPN536) | Prostate, Ovarian Cancer | Heterodimer Validation (Need Cross-reactive Abs & Lentivirus for stable lines) |
| CAR-T / Cell Therapy | Multiple Biotechs | Advanced Carcinomas | Activation Assay (Need Native Glycosylated Antigens) |